New hope for older leukemia patients: safer transplant prep may boost survival

NCT ID NCT07500753

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Apr 07, 2026 · Last updated May 21, 2026 · Updated 7 times

Summary

This study tests a new combination of drugs (cladribine, lisaftolax, and busulfan) given before a stem cell transplant in people aged 50 and older with relapsed or hard-to-treat acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to make the transplant safer and more effective, helping patients live longer without the cancer coming back. About 30 participants will be enrolled to see if this approach improves survival and reduces side effects compared to standard treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215006, China

Conditions

Explore the condition pages connected to this study.

MDS (MYELODYSPLASTIC SYNDROME) RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)